Does ICU sedative Dex blunt kidney ferroptosis after I/R?
In mice and kidney cells, dexmedetomidine lessened ferroptosis-linked renal I/R injury by restraining ACSL4 through α2-AR.
Source
Dexmedetomidine Attenuates Ferroptosis-Mediated Renal Ischemia/Reperfusion Injury and Inflammation by Inhibiting ACSL4 <i>via</i> α2-AR
Study at a glance
- Design
- Animal / in-vitro — Mouse bilateral renal I/R (45 min/48 h) plus HEK293T OGD/R with Dex and ACSL4/α2-AR manipulations
- N
- Multiple animal/cell assay groups; no single primary clinical N
- Population
- C57BL/6 mice and HEK293T cells under renal I/R or OGD/R stress
- Outcome
- Ferroptosis, inflammation, and ACSL4 signaling after Dex via α2-AR
Structured fields used in claim comparison tables when every cited study has a complete layer.
What they did
Investigators induced bilateral renal hilum ischemia (45 min) and 48 h reperfusion in C57BL/6 mice, ran RNA-seq, and modeled injury with HEK293T OGD/R plus Dex (1 μM), ACSL4 overexpression, and α2-AR inhibition.
What they found
Dex reduced tissue injury, ferroptosis, and inflammation alongside lower ACSL4; ACSL4 overexpression or α2-AR inhibitor–driven ACSL4 rise reversed Dex protection.
The limits
What it doesn't show
No human AKI trial; clinical dosing, safety in transplant/shock, and causality beyond these models remain open.
Key terms
- Dexmedetomidine (Dex)
- Highly selective α2-adrenergic agonist used clinically for sedation; tested here against renal I/R ferroptosis.
- Ferroptosis
- Iron-dependent cell death driven by phospholipid peroxidation.
- ACSL4
- Acyl-CoA synthetase long-chain family member 4; promotes ferroptosis-prone lipid remodeling.
- Renal I/R
- Ischemia–reperfusion insult to the kidney, a common AKI mechanism.
- OGD/R
- Oxygen-glucose deprivation/reoxygenation cell model of ischemic stress.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
What is the primary experimental setting of this paper?
Common questions
Is Dex proven for human AKI here?
No—the conclusion is a preclinical suggestion only.
Why ACSL4?
It esterifies polyunsaturated fatty acids into membranes prone to ferroptotic peroxidation; Dex appears to suppress it via α2-AR.
What reversed Dex’s benefit?
ACSL4 overexpression and α2-AR inhibitor–linked ACSL4 induction.
What injury timing was used in mice?
45 minutes ischemia, then 48 hours reperfusion.
More on Critical care